HPV vaccine（Cecolin®）by Innovax Officially Entered the Evaluation Stage in its WHO Prequalification
Submitted on Jan.20th, the screening of the Innovax HPV vaccine technical dossier has been completed. On Mar. 16th, the vaccine is officially accepted by WHO for Prequalification evaluation. （Ref. #.: I8-370-43 WPRO（2020-063））
It is a remarkable milestone for Innovax to enter the international markets.With the efforts made through WHO prequalification, one of the main target is to become supplier in the United Nations Procurement Market.
World Health Organization issued a call foraction towards global cervical cancer elimination in May 2018. Global HPV vaccine supply availability is currently insufficient to meet the aggregate demand. INNOVAX is committed to making a Safe, effective and cost-conscious vaccine,available for more females worldwide. Being prequalified, Innovax will not only help alleviate the global shortage of HPV vaccine, but also play an important role towards the global elimination of cervical cancer.
AboutInnovax
Xiamen Innovax Biotech Co., Ltd. (INNOVAX)is a leading company in the field of developing, manufacturing and marketinginnovative vaccines with its headquarters and manufacture based in Xiamen,China.
In collaboration with the NationalInstitute of Diagnostics and Vaccine Development in Infectious Diseases(NIDVD), Innovax has established a core-platform using DNA recombinanttechnology to express protein in E. coli for vaccine production. Based on thisplatform, the world’s first Hepatitis E Vaccine, Hecolin® has launched in Chinain October 2012. In addition, its Cervical Cancer Vaccine--Cecolin® (HPV16&18 bivalent,) have been approved in 2019. Furthermore, a 9-valent HPVvaccine is now in phase II clinical trial. For further information please visit http://www.innovax.cn/en/index.aspx.
